



A0000434-01-CFP

### IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT:

ANDRIANJARA, C., ET AL.

**EXAMINER:** 

SERIAL NO:

10/075,069

ART UNIT:

**FILED** 

FEBRUARY 13, 2002

PAPER NO:

FOR

MATRIX METALLOPROTEINASE INHIBITORS

### AMENDMENT AND RESPONSE

April 25, 2002

Commissioner for Patents U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

#### Dear Sir:

This letter is responsive to a Notice to File Corrected Application Papers dated March 12, 2002, in United States nonprovisional patent application serial number 10/075,069, filed February 13, 2002, which claims benefit of priority from United States provisional application serial number 60/268,821, filed February 14, 2001.

### IN THE APPLICATION:

Please enter the enclosed substitute set of drawings containing Figures 1, 1A, and 2 to 9 on ten pages into the application.

Please enter the enclosed initial computer readable form copy of the sequence listing of instant Figures 1 and 1A, and the initial paper copy of the same sequence listing into the application.

Andrianjara et al.

- 2 -

10/075,069

# <u>IN THE SPECIFICATION</u>:

On page 16, please delete line 30, and insert instead the following:

"Fig. 1 and Fig. 1A contain a sequence listing for MMP-13 which is SEQ

ID NO:001;"

10/075,069

#### REMARKS

United States nonprovisional patent application serial number 10/075,069, filed February 13, 2002, contained a sequence listing in Figure 1 on two pages and a set of color drawings in Figures 2 to 9 on eight pages. The application, specification, and drawings are amended by:

- An amendment to the brief description of Figure 1 in the specification;
- Submission of a set of substitute drawings;
- Submission of an initial computer readable form (CRF) copy on a 3.5 inch diskette of the sequence listing of original Figure 1; and
- Submission of an initial paper copy of the same sequence listing.

The above-identified amendments will be all of the amendments made if the instant amendments are entered. No new matter is added.

Attached hereto on a separate sheet entitled "Version with markings to show changes made." is a version of the above amendments with the changes marked.

A Notice to File Corrected Application Papers dated March 12, 2002 (COPY ENCLOSED), was issued by the Office of Initial Patent Examination ("OIPE") which alleged that

- "drawings submitted to the Office are not electronically reproducible";
   and
- the application "clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825."

The OPIE requested Applicants provide the following items:

- "substitute drawings in compliance with 37 CFR 1.84" (see 37 CFR 1.84(e)); and
- "an initial computer readable form (CRF) copy of the 'Sequence Listing', an initial paper or compact disk copy of the 'Sequence Listing', as well as

an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d)."

# Drawing Requirements under 37 CFR § 1.84(e)

Enclosed with this Amendment and Response is a substitute set of drawings containing Figures 1, 1A, and 2 to 9 on ten pages. Please replace the set of original drawings in the application with the instant set of substitute drawings.

In all of the substitute drawings, all "Figure" headings are amended to instead recite "FIG."; certain lower case text in the figures is capitalized; and all figures are placed on paper that satisfies the requirements of 37 CFR 1.84(e), in accordance with preferred U.S. drawing requirements.

Original Figures 2 to 9 are further amended from color drawings to black and white drawings.

Further regarding original Figure 1, the original sequence listing on two pages, namely pages 1/10 and 2/10, has not been amended, but a further amendment that inserts the heading "FIG. 1A" on page 2/10 is made in accordance with preferred U.S. drawing requirements.

Regarding original Figure 2, a further amendment is made to insert white boxes around certain textual labels for the convenience of the Examiner.

Regarding original Figure 3, a further amendment is made that moves certain amino acid labels for amino acids in the drawing off of the drawing, and inserts arrows

from the moved labels to the respective amino acids, for the convenience of the Examiner.

Support for the amendments to the drawings is found in original Figures 1 to 9. No new matter has been added.

### Sequence Listing Requirements under 37 CFR §§ 1.821-1.825

Enclosed with this amendment is an initial computer readable form (CRF) copy on a 3.5-inch diskette of the sequence listing of original Figure 1, and an initial paper copy of the same sequence listing. As requested above, please enter the enclosed initial computer readable form copy of the sequence listing of instant Figure 1 and the initial paper copy of the same sequence listing into the application. Support for the amendment is found in original Figure 1.

I hereby certify that the information contained in the enclosed paper copy of the Sequence Listing is identical to the information contained in the enclosed computer readable disk, and that the Sequence Listing does not contain new matter. A Sequence Listing certificate with a signed certification to this effect is enclosed herewith.

In view of the above amendment and remarks, Applicants deem the application complies with the requirements of 37 C.F.R. 1.84 and 37 C.F.R. 1.821-1.825. Applicants request that the application be accepted as a formal application, and that the application be examined on the merits.

The Commissioner is hereby authorized to charge any fees that may be required, or credit any overpayment, to deposit account number 23-0455.

The undersigned would welcome a telephone call from the Examiner to discuss any matters related to this case.

10/075,069

Respectfully submitted,

<u>Ulude F. Purchase</u> J. Claude F. Purchase, Jr.

Reg. No. 47,871

Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-1692

Fax (734) 622-1553

Enc. Copy of Notice to File Corrected Application Papers (2 pages)

Substitute set of drawings (10 pages)

Initial computer readable form (CRF) copy on a 3.5-inch diskette of the sequence

listing of original Figure 1 (1 diskette)

Initial paper copy of the same sequence listing (2 pages)

Sequence Listing Certificate

- 7 -

10/075,069

## Version with markings to show changes made.

## **IN THE APPLICATION:**

A substitute set of drawings containing Figures 1, 1A, and 2 to 9 on ten pages is entered into the application.

An initial computer readable form (CRF) copy on a 3.5 inch diskette of the sequence listing of original Figure 1, and an initial paper copy of the same sequence listing, are entered into the application.

# **IN THE SPECIFICATION:**

Line 30 on page 16, at line 30, is amended as follows:

"Fig. 1 [is] and Fig. 1A contain a sequence listing for MMP-13 which is SEQ ID NO:001;"